Arbutus Biopharma Corp (ABUS)
2.71
+0.03
(+1.12%)
USD |
NASDAQ |
May 03, 16:00
2.715
0.00 (0.00%)
After-Hours: 20:00
Arbutus Biopharma Free Cash Flow: -86.94M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -86.94M |
| September 30, 2023 | -86.78M |
| June 30, 2023 | -83.74M |
| March 31, 2023 | -83.83M |
| December 31, 2022 | -35.87M |
| September 30, 2022 | -38.41M |
| June 30, 2022 | -35.68M |
| March 31, 2022 | -29.82M |
| December 31, 2021 | -68.34M |
| September 30, 2021 | -63.84M |
| June 30, 2021 | -59.97M |
| March 31, 2021 | -54.20M |
| December 31, 2020 | -51.67M |
| September 30, 2020 | -49.92M |
| June 30, 2020 | -61.46M |
| March 31, 2020 | -70.44M |
| December 31, 2019 | -71.60M |
| September 30, 2019 | -75.48M |
| June 30, 2019 | -65.20M |
| March 31, 2019 | -65.40M |
| December 31, 2018 | -69.00M |
| September 30, 2018 | -62.23M |
| June 30, 2018 | -65.01M |
| March 31, 2018 | -55.16M |
| December 31, 2017 | -55.90M |
| Date | Value |
|---|---|
| September 30, 2017 | -62.80M |
| June 30, 2017 | -61.46M |
| March 31, 2017 | -71.02M |
| December 31, 2016 | -61.88M |
| September 30, 2016 | -63.85M |
| June 30, 2016 | -52.08M |
| March 31, 2016 | -52.51M |
| December 31, 2015 | -58.67M |
| September 30, 2015 | -46.45M |
| June 30, 2015 | -50.21M |
| March 31, 2015 | -40.28M |
| December 31, 2014 | -13.48M |
| September 30, 2014 | -3.935M |
| June 30, 2014 | -0.853M |
| March 31, 2014 | 4.399M |
| December 31, 2013 | -7.462M |
| September 30, 2013 | 30.52M |
| June 30, 2013 | 32.80M |
| March 31, 2013 | 34.11M |
| December 31, 2012 | 32.89M |
| September 30, 2012 | -7.914M |
| June 30, 2012 | -6.457M |
| March 31, 2012 | -8.950M |
| December 31, 2011 | -7.891M |
| September 30, 2011 | -11.25M |
Free Cash Flow Range, Past 5 Years
-86.94M
Minimum
Dec 2023
-29.82M
Maximum
Mar 2022
-61.75M
Average
-63.84M
Median
Sep 2021
Free Cash Flow Benchmarks
| Moderna Inc | -3.672B |
| Pacira BioSciences Inc | 139.49M |
| Chimerix Inc | -69.18M |
| Karyopharm Therapeutics Inc | -92.72M |
| Corvus Pharmaceuticals Inc | -23.97M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -17.29M |
| Cash from Investing (Quarterly) | 22.22M |
| Cash from Financing (Quarterly) | 3.807M |
| Free Cash Flow Per Share (Quarterly) | -0.1026 |
| Free Cash Flow to Equity (Quarterly) | -17.29M |
| Free Cash Flow to Firm (Quarterly) | -17.29M |
| Free Cash Flow Yield | -19.33% |